Scientific Session
Immunobiology
Michael Balzer, MD
Charité Universitätsmedizin Berlin
Berlin, Germany
Disclosure(s): AstraZeneca: Ownership Interest (Ongoing); Bayer: Ownership Interest (Ongoing); BioNTech: Ownership Interest (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing); CureVac: Ownership Interest (Ongoing); Linde: Ownership Interest (Ongoing); Moderna: Ownership Interest (Ongoing); Pfizer: Ownership Interest (Ongoing)